Form 4: CalciMedica CEO Rachel Leheny Acquires 115,000 Stock Options
SEC Form 4 Filing
CalciMedica's CEO, Rachel Leheny, reports the acquisition of 115,000 employee stock options.
Summary
- Rachel Leheny, CEO of CalciMedica, Inc., filed a Form 4 with the SEC.
- The filing reports the acquisition of 115,000 employee stock options on August 27, 2024.
- The exercise price of the options is $4.16.
- The options vest in equal monthly installments over a four-year period following March 28, 2024, with an expiration date of August 26, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing about stock option grants, which doesn't inherently indicate positive or negative sentiment.
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company executives.
Stakeholder Impact
- The acquisition of stock options by the CEO could potentially align her interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| March 28, 2024 | Start date for monthly vesting of the stock options over a four-year period. |
| August 27, 2024 | Date of transaction: CEO Rachel Leheny acquired 115,000 employee stock options. |
| August 26, 2034 | Expiration date of the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.